

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-703-872-9306:

PATENT  
Attorney Docket No.: 15270J-004764US  
Client Ref. No.: 209-US-CIP8BC4

On May 22, 2002  
TOWNSEND and TOWNSEND and CREW LLP  
By: Rosemarie L. Celli  
Rosemarie L. Celli

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DALE B. SCHENK et al.

Application No.: 09/724,551

Filed: November 28, 2000

For: PREVENTION AND TREATMENT  
OF AMYLOIDOGENIC DISEASE

Examiner: Sharon L. Turner

Art Unit: 1647

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office  
Box Sequence, P.O. Box 2327  
Arlington, VA 22202

Sir:

Applicants submit herewith the required paper copy of the Sequence Listing. Applicants have concurrently filed Request To Reference Previously Filed Identical Computer Readable Copy According To 37 CFR 1.821(e); and, therefore, Applicants have not submitted computer readable copy of the sequence listing herewith.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows:

IN THE SPECIFICATION:

The paragraph beginning at page 7, line 32, has been amended as follows:

Fig. 19: Epitope Map: Restricted N-terminal Response. Day 175 serum from cynomolgus monkeys was tested by ELISA against a series of 10-mer overlapping peptides (SEQ ID NOS:1-41) covering the complete AN1792 sequence. Animal number